What Lexaria Bioscience Corp. does.

Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECH TM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.

DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs (“GLP-1”) and glucose-dependent insulinotropic polypeptide drugs (“GIP”), vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids. Our technology can be applied to a variety of therapeutic indications, including diabetes, weight loss, epilepsy, hypertension and heart disease. DehydraTECH can be implemented in a multitude of ingestible product formats including oral suspensions, tablets, capsules, foods, beverages, and oral pouches. It is suitable for use with a variety of product formats including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.

Revenue and profit, by fiscal year.

More on LEXX.

• Lexaria Bioscience Corp. summary
• Lexaria Bioscience Corp. financial statements
• Lexaria Bioscience Corp. key metrics
• Lexaria Bioscience Corp. health scores and style box
• Lexaria Bioscience Corp. earnings
• Lexaria Bioscience Corp. dividends
• Lexaria Bioscience Corp. valuation
• Lexaria Bioscience Corp. ownership and insiders
• Lexaria Bioscience Corp. peers

Figures from Lexaria Bioscience Corp.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.